The idea of the U.S. Food and Drug Administration collecting standardised quality metrics from every drug manufacturer that ships to the U.S. is now more than a decade old. Congress asked for it in the 2012 FDA Safety and Innovation Act. FDA published draft guidance in 2015 and revised it in 2016. Industry pushback was substantial, and the mandatory reporting program never launched. What did launch instead is a slower, voluntary track that has spent a full decade edging toward the same objective from a different angle. As of 2026 that track is called the Quality Management Maturity program, and its third assessment cycle is underway.

For laboratories that run analytical procedures for lot release and stability, this arc matters because the metrics FDA cares about most - the ones that recur across every draft, docket, and pilot - come out of the analytical lab. Understanding where the program stands now is easier if you know where it has been.

What “Quality Metrics” was supposed to be

The 2015 and revised 2016 draft guidance proposed that FDA would receive four site-level metrics annually from every covered establishment: lot acceptance rate, product quality complaint rate, invalidated out-of-specification rate, and (with some later refinement) an annual product review on-time rate. Three of the four had a direct or indirect analytical component. The invalidated OOS rate (IOOSR) was the most explicitly laboratory-facing: the count of OOS lot-release and stability results invalidated by the establishment because of an aberration in the measurement process, divided by the total OOS results in the same period.

The framing of IOOSR is worth restating because it has not really changed since 2016: FDA reads a high invalidation rate as a signal that a laboratory is either (a) generating OOS results that the analytical method itself is producing, or (b) invalidating real OOS results for procedural reasons rather than measurement failures. Both are supposed to be visible from outside.

Industry objected to the mandatory reporting proposal on several grounds - definitional ambiguity, the risk of gaming, the burden of continuous reporting. FDA never published a final Quality Metrics rule. The Federal Register notice from March 2022 reopened the docket and effectively asked whether reporting should look different. It did not resurrect the 2016 metric definitions verbatim.

The Feedback Program and its lessons

Between the 2016 draft and the 2022 docket, FDA ran two voluntary pilots announced in June 2018: a Site Visit Program and a Quality Metrics Feedback Program. Both were meant to let the agency see how establishments were actually calculating and using metrics before insisting on a national reporting regime. The pilot lessons paper published in AAPS Open in 2023 is the most concrete public account of what CDER learned: definitions of even the four proposed metrics varied widely across firms; the same OOS event could be classified differently at different sites of the same company; and the analytical procedure lifecycle - method transfer, method robustness, method updates - was often the underlying driver of metric variability.

That is the finding most relevant to laboratories: the pilots concluded that metric numbers alone were not diagnostic. Context around the analytical method producing the numbers was what let FDA reviewers interpret them.

QMM as the successor

The current program, CDER’s Quality Management Maturity assessment, is not a metrics reporting program. It is a maturity assessment. A CDER team of three staff visits a volunteer establishment (on-site or hybrid), evaluates practice across five areas - management commitment to quality, business continuity, technical excellence, advanced pharmaceutical quality system, employee empowerment and engagement - and returns a report scoring performance and naming improvement opportunities. Two follow-up meetings at three and six months track the improvement plan.

The Federal Register notice from April 2025 established the second year of the protocol evaluation. FDA announced the third year on 11 February 2026, again capped at nine establishments, with applications open through 13 April 2026. Eligibility requires prior surveillance inspection with NAI or VAI classification, active CDER-regulated commercial distribution, and consent to on-site or hybrid assessment.

Two of the five QMM practice areas - technical excellence, and advanced pharmaceutical quality system - are where analytical procedure content lives. Technical excellence covers process and analytical method understanding, control strategy design, and knowledge management around methods. The advanced pharmaceutical quality system area covers the ICH Q10 mechanics of change control, deviation and OOS handling, and CAPA effectiveness. Analytical laboratories touch both.

What it means for analytical procedure data

For a laboratory that runs release and stability testing, the shift from Quality Metrics reporting to QMM assessment changes the question FDA asks. The 2016 draft asked “what is your IOOSR?” The QMM protocol asks how the laboratory established its analytical methods, how it manages method lifecycle under ICH Q14 and Q2(R2), how OOS investigations are structured, and whether the establishment can show that the method itself - not just the compliance system around it - is genuinely fit for purpose.

That matches what other regulators have been doing on the analytical side. The EMA and PMDA are both working the analytical procedure lifecycle through parallel ICH-aligned mechanisms, and the FDA Emerging Technology and Advanced Manufacturing Technology programs sit alongside QMM as the vehicles for methods that go beyond the compendial baseline. QMM is the piece that ties assessment of laboratory maturity back to the wider pharmaceutical quality system rather than to a spreadsheet of four numbers per site per year.

Practical implications now

The QMM program is voluntary and the annual cohort is small - nine establishments per year for three years is 27 sites out of a U.S. and imported drug manufacturing base that runs into the thousands. Its direct compliance footprint is limited. Its indirect effect on analytical laboratories is not.

Two things are worth tracking. First, the QMM assessment tool is being refined publicly each cycle. The dimensions FDA is testing on volunteers today are the dimensions likely to show up in future inspection expectations, in Warning Letter language, and in the pharmaceutical quality assessment work that supports approval. Laboratories that can already articulate their analytical procedure lifecycle in the vocabulary QMM uses - technical excellence, control strategy, knowledge management, procedural performance versus true measurement performance - will find that vocabulary showing up on the inspection side in due course.

Second, the invalidated OOS rate is not gone. FDA continues to treat OOS handling as a diagnostic surface. The 2016 draft may not have become a rule, but the metric it defined remains the shortest public statement of how FDA reads a laboratory’s own view of its measurement reliability. Laboratories that generate OOS results the analytical method itself is producing, or that invalidate real OOS results for procedural convenience, will still be visible - just under a different program name.